The production and use of cells as therapeutic agents in neurodegenerative diseases.
Although progressive neurodegenerative diseases have very different and highly specific causes, the dysfunction or loss of a vulnerable group of neurons is common to all these disorders and may allow the development of similar therapeutic approaches to the treatment of diseases such as amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease. When a disease is diagnosed, the first step is to instigate protective measures to prevent further degeneration. However, most patients are symptom-free until almost all of the vulnerable cells have become dysfunctional or have died. There are known molecular mechanisms and processes in stem cells and progenitor cells that may be of use in the future design and selection of cell-based replacement therapies for neurological diseases. This review provides examples of conceptual and clinical problems that have been encountered in the development of cell-based treatments, and specific criteria for the effective use of cells in the future treatment of neurodegenerative diseases.
Isacson
Ole
O
Department of Neurology and the Harvard Center for Neurodegeneration and Repair, Harvard Medical School, Boston, MA, USA. isacson@hms.harvard.edu <isacson@hms.harvard.edu>
D000818:Animals; D001921:Brain / Q000473:pathology; D016380:Brain Tissue Transplantation / Q000379:methods*; D002454:Cell Differentiation; D016332:Fetal Tissue Transplantation / Q000379:methods*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000628:therapy*; D009474:Neurons / Q000637:transplantation*; D013234:Stem Cells / Q000166:cytology